ID19419A - Senyawa-senyawa penghambat sintetase skualena - Google Patents

Senyawa-senyawa penghambat sintetase skualena

Info

Publication number
ID19419A
ID19419A IDP972091A ID972091A ID19419A ID 19419 A ID19419 A ID 19419A ID P972091 A IDP972091 A ID P972091A ID 972091 A ID972091 A ID 972091A ID 19419 A ID19419 A ID 19419A
Authority
ID
Indonesia
Prior art keywords
synetase
skualena
compounding
compounds
synetase skualena
Prior art date
Application number
IDP972091A
Other languages
English (en)
Inventor
Ernest Seiichi Hamanaka
Cheryl Myers Hayward
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID19419A publication Critical patent/ID19419A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
IDP972091A 1996-06-20 1997-06-19 Senyawa-senyawa penghambat sintetase skualena ID19419A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2236596P 1996-06-20 1996-06-20

Publications (1)

Publication Number Publication Date
ID19419A true ID19419A (id) 1998-07-09

Family

ID=21809221

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP972091A ID19419A (id) 1996-06-20 1997-06-19 Senyawa-senyawa penghambat sintetase skualena

Country Status (8)

Country Link
US (1) US6537987B1 (id)
AP (1) AP9701018A0 (id)
AU (1) AU2401697A (id)
GT (1) GT199700069A (id)
ID (1) ID19419A (id)
MA (1) MA24215A1 (id)
TN (1) TNSN97105A1 (id)
WO (1) WO1997048701A1 (id)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE401315T1 (de) * 1995-09-13 2008-08-15 Takeda Pharmaceutical 5-(2,3-dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische mittel
US20060141036A1 (en) 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
KR100592842B1 (ko) * 1998-01-28 2006-06-26 워너-램버트 캄파니 엘엘씨 알츠하이머병의 치료 방법
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
EP1407782A4 (en) * 2001-06-28 2004-10-20 Takeda Chemical Industries Ltd AGENTS FOR PREVENTION / TREATMENT OF FUNCTIONAL ORGANIC DISEASES AND ORGANIC DYSFUNCTION
US6984645B2 (en) 2001-11-16 2006-01-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
WO2003094909A2 (en) * 2002-05-09 2003-11-20 Enos Pharmaceuticals, Inc. Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
DE102004001871A1 (de) * 2004-01-14 2005-09-01 Bayer Healthcare Ag Tricyclische Benzazepin-Derivate und ihre Verwendung
DE102004006325A1 (de) * 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2-on-Derivate und ihre Verwendung
US7323455B2 (en) 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US7572805B2 (en) 2004-07-14 2009-08-11 Bristol-Myers Squibb Company Pyrrolo(oxo)isoquinolines as 5HT ligands
BRPI0514193A (pt) * 2004-08-09 2008-06-03 Takeda Pharmaceutical agente de diminuição de crp, método para previnir e/ou tratar uma doença envolvida em elevação de crp, e, uso de um composto tendo uma atividade inibitória de esqualeno sintase, ou uma pró-droga do mesmo, ou um sal do mesmo
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
ES2319461T3 (es) 2005-02-10 2009-05-07 Bristol-Myers Squibb Company Dihidroquinazolinonas como moduladores de 5ht.
BRPI0608469A2 (pt) * 2005-04-22 2010-01-05 Alantos Pharmaceuticals Holding Inc inibidores de dipeptidil peptidase-iv
AR054368A1 (es) * 2005-06-01 2007-06-20 Takeda Pharmaceutical Metodo para tratar hiperlipidemia
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US7795436B2 (en) 2005-08-24 2010-09-14 Bristol-Myers Squibb Company Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
TW200730503A (en) * 2005-10-21 2007-08-16 Daiichi Seiyaku Co Tricyclic compound
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
DE102006031176A1 (de) * 2006-07-06 2008-01-10 Bayer Healthcare Ag Substituierte Benzoxepino-isoxazole und ihre Verwendung
FR2904002A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
AU2010229653A1 (en) 2009-03-27 2011-10-20 Astrazeneca Ab Methods for preventing major adverse cardiovascular events with DPP-IV inhibitors
EP2892897A1 (en) 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
WO2014039411A1 (en) 2012-09-05 2014-03-13 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
CN106543102B (zh) * 2016-10-28 2018-09-14 石家庄学院 1,5-苯并硫氮杂卓类衍生物及其应用
PE20210644A1 (es) 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
CN118666865A (zh) * 2023-03-17 2024-09-20 中山大学 手性或消旋的嘧啶并七元氧氮杂环类化合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG82630A1 (en) * 1992-04-20 2001-08-21 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
EP0782451A1 (en) * 1994-09-20 1997-07-09 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
FI972696A0 (fi) * 1994-12-23 1997-06-23 Pfizer Naftyyli-bentsoksatsepiinit tai -bentsotiatsepiinit
EP0862562B1 (en) * 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
ATE401315T1 (de) * 1995-09-13 2008-08-15 Takeda Pharmaceutical 5-(2,3-dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische mittel
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors

Also Published As

Publication number Publication date
US6537987B1 (en) 2003-03-25
AU2401697A (en) 1998-01-07
AP9701018A0 (en) 1997-07-31
TNSN97105A1 (fr) 2005-03-15
WO1997048701A1 (en) 1997-12-24
GT199700069A (es) 1998-11-24
MA24215A1 (fr) 1997-12-31

Similar Documents

Publication Publication Date Title
ID19419A (id) Senyawa-senyawa penghambat sintetase skualena
ID19609A (id) Senyawa-senyawa heterosiklik
ID19403A (id) Senyawa-senyawa heterosiklik
ID16152A (id) Senyawa-senyawa triaril
ID15904A (id) Senyawa-senyawa tiofenopirimidina
ID19430A (id) Senyawa senyawa heterosiklik
BR9709230A (pt) Composto
ID19476A (id) Senyawa piridilpirol
ID22850A (id) Senyawa-senyawa pirazina
BR9707051A (pt) Composto
ID18685A (id) Senyawa trisiklik tersubstitusi
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
DE69716924D1 (de) Phosphonat-nukleotid-verbindungen
EE9900448A (et) Ühendid
PT906288E (pt) Novos compostos
BR9705635A (pt) Compostos
DE69733514D1 (de) Kautschukmischung
BR9711205A (pt) Composto
DK0923594T3 (da) Bromotiacumicinforbindelser
EE9900475A (et) Ühendid
DE69709659D1 (de) Halopropargyl-einschlussverbindungen
EE9900602A (et) Ühendid
EE9900012A (et) Uudsed ühendid
ID22983A (id) Senyawa-senyawa fluorometoksimino
EE9900466A (et) Ühendid